Business Context and Reporting Period
This Form 8-K, dated May 10, 2017, serves as a supplemental disclosure to the definitive proxy statement filed by ADMA Biologics, Inc. on April 26, 2017. The filing addresses a putative class action lawsuit challenging the proposed acquisition of the Biotest Pharmaceuticals Corporation (BPC) Therapy Business Unit. The Company intends to close the transaction at its annual meeting on May 25, 2017, which includes issuing approximately 50% of its equity to Biotest.
Key Financial Metrics and Transaction Details
- Transaction Consideration: The Company will issue 4,295,580 shares of common stock (25%) and 8,591,160 shares of non-voting common stock (convertible) to the Seller, representing a 50% equity interest.
- Asset Valuation: An independent expert appraised the Boca Facility (land and building) at $20,000,000. After deducting $811,000 in building depreciation, the aggregate value captured in the purchase price allocation is $19,189,000.
- Projected Margins: Management forecasts that the lead product candidate, RI-002, will achieve a gross margin of 60-70% post-transaction, compared to a forecasted 40-50% without the transaction.
- Advisory Fees: Over the two years preceding the fairness opinion, the Company paid Raymond James a total of $1,785,050, including $650,000 for the fairness opinion and fees for prior equity offerings.
Material Changes and Supplemental Disclosures
The filing provides specific updates to the original proxy statement to address litigation concerns:
- Manufacturing Continuity: Clarified that ADMA has an existing agreement with a contract filler for the Boca Facility, eliminating the risk of service interruption post-closing.
- Financial Projections: Revised language to state that financial projections were prepared by ADMA management with input from Biotest management solely for internal purposes.
- Comparable Companies: Updated the list of selected comparable companies and their 2016E TEV/Revenue multiples (ranging from 1.5x to 7.2x).
Outlook, Risks, and Contingencies
Outlook and Synergies: The primary strategic benefit is the elimination of third-party manufacturing fees currently paid to Biotest, expected to significantly improve gross margins. Additional cost savings are anticipated from personnel synergies and headcount reductions.
Risks and Contingencies:
- Litigation: A lawsuit (Johnathan English v. ADMA Biologics, Inc.) alleges material omissions in the proxy statement and seeks to enjoin the transaction. The Company denies the allegations but issued this supplement to mitigate litigation risks.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in product development, regulatory approval, and the completion of the transaction.
Investor Verification Checklist
- Verify the status of the class action lawsuit (Johnathan English v. ADMA Biologics, Inc.) and any potential injunctions.
- Confirm the final terms of the contract filler agreement for the Boca Facility to ensure no service interruption.
- Review the assumptions underlying the projected 60-70% gross margin for RI-002.
- Assess the impact of the 50% equity dilution on existing shareholders' voting power and economic interest.
- Validate the $19,189,000 valuation of the Boca Facility against independent market data.